Skip to content

A Randomized Controlled Trial of Yiqi Yangxin Anshen Oral Solution for Chronic Insomnia Disorder

A Randomized Controlled Trial of Yiqi Yangxin Anshen Oral Solution for Chronic Insomnia Disorder

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025002591
Enrollment
Unknown
Registered
2025-12-29
Start date
2025-12-30
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic insomnia (Western medical diagnosis) and insomnia (heart and liver blood deficiency syndrome) (Traditional Chinese Medical diagnosis)

Interventions

Experimental Group:Yiqi Yangxin Anshen Oral Liquid, 1 vial each time, 3 times daily, 1 hour after meals by mouth.
Control Group:Yi Qi Yang Xin An Shen Oral Liquid Placebo, 1 vial each time, 3 times daily, to be taken orally 1 hour after meals.

Sponsors

Guangdong Provincial Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) Aged between 18 and 70 years old; (2) Meeting the diagnostic criteria for chronic insomnia in Western medicine; (3) Meeting the diagnostic criteria for insomnia () in Traditional Chinese Medicine; (4) Meeting the criteria for deficiency of heart and liver blood syndrome; (5) Having signed the informed consent form.

Exclusion criteria

Exclusion criteria: (1) Individuals preparing for pregnancy, during pregnancy, breastfeeding, or those who need to accompany children while sleeping; (2) Patients confirmed by medical history and consultation to have secondary insomnia caused by other diseases, such as restless legs syndrome, acute or chronic heart failure, chronic obstructive pulmonary disease, or acute or chronic bronchitis; (3) Patients diagnosed with severe depression using the Patient Health Questionnaire-9 (PHQ-9) (total score =15) or diagnosed with severe anxiety using the Generalized Anxiety Disorder-7 (GAD-7) scale (total score =15); (4) Patients classified as having severe insomnia based on the Insomnia Severity Index (ISI) (total score =22); (5) Patients with cancer and a remission period of less than 5 years; (6) Individuals who have participated in other drug clinical trials within the past 30 days; (7) Patients with other mental disorders; (8) Patients with hemoglobin levels below 90 g/L, white blood cell counts less than 3.0 × 10^9/L, or platelet counts below 100 × 10^9/L; (9) Patients with a glomerular filtration rate below 40 ml/min; (10) Patients with aspartate aminotransferase or alanine aminotransferase levels exceeding 1.5 times the upper limit of the normal range; (11) Night shift or rotating shift workers and individuals with irregular bedtime schedules (i.e., bedtime outside of 9 PM and midnight); (12) Patients allergic to the investigational drug; (13) Patients with finger or nail injuries, severe skin diseases, or skin damage, absent fingers, or non-removable jewelry on the wrist; (14) Patients with metal implants or pacemakers in the body.

Design outcomes

Primary

MeasureTime frame
Insomnia Severity Index;

Secondary

MeasureTime frame
Pittsburgh Sleep Quality Index Scale;Depression Screening Tool;Generalized Anxiety Disorder Scale;Traditional Chinese Medicine Deficiency and Excess Scale;Traditional Chinese Medicine Constitution Scale;Pulse Meter;Human Bioelectromagnetic Induction;Nail fold vascular microcirculation;

Countries

China

Contacts

Public ContactYang Zhimi

Guangdong Provincial Hospital of Traditional Chinese Medicine

yangyovip@126.com13822296363

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026